Trademarkia Logo

Canada

C$
LIPINUMENT
REGISTERED

on 16 Aug 2024

Last Applicant/ Owned by

REGENERON PHARMACEUTICALS INC.

777 Old Saw Mill River RoadTarrytown, NY 10591

US

Serial Number

1978407 filed on 31st Jul 2019

Registration Number

TMA1250538 registered on 16th Aug 2024

Registration expiry Date

16th Aug 2034

Correspondent Address

GOWLING WLG (CANADA) LLP

SUITE 16001 FIRST CANADIAN PLACE100 KING STREET WESTTORONTO

ONTARIO

CA

M5X1G5

LIPINUMENT

Trademark usage description

pharmaceutical preparations for treatment of cardiovascular diseases allergy medications; anti-inflammatory pharmaceutical preparations; anti-viral a Read More

Classification Information


Class [005]
Allergy medications; anti-inflammatory pharmaceutical preparations; anti-viral agents; antiallergic medicines; cardiovascular pharmaceuticals; pharmaceutical preparations and substances for the treatment of gastrointestinal diseases; pharmaceutical preparations for the prevention and treatment of metabolic diseases and disorders, namely diabetes, gout, arthritis and anemia; pharmaceutical preparations for the prevention and treatment of muscular atrophy; pharmaceutical preparations for the relief of pain; pharmaceutical preparations for the treatment of autoimmune diseases; pharmaceutical preparations for the treatment of bacterial skin infections, fungal skin infections, viral skin infections and parasitic skin infections; pharmaceutical preparations for the treatment of bone diseases; pharmaceutical preparations for the treatment of bone fractures; pharmaceutical preparations for the treatment of chronic pain; pharmaceutical preparations for the treatment of genetic disorders; pharmaceutical preparations for the treatment of genitourinary diseases, namely, urological diseases, infertility, sexually transmitted diseases, inflammatory pelvic diseases; pharmaceutical preparations for the treatment of hematological diseases and disorders; pharmaceutical preparations for the treatment of hepatological diseases and disorders; pharmaceutical preparations for the treatment of immunologic diseases, namely, autoimmune diseases, immunologic deficiency syndromes; pharmaceutical preparations for the treatment of infectious diseases, namely respiratory infections, eye infections; pharmaceutical preparations for the treatment of metabolic diseases and disorders, namely diabetes, hypoglycaemia, gout, osteoarthritis, muscular dystrophy, anemia; pharmaceutical preparations for the treatment of metabolic disorders, namely diabetes, bulimia nervosa, anorexia, obesity and hypothyroidism; pharmaceutical preparations for the treatment of musculoskeletal disorders; pharmaceutical preparations for the treatment of neurological diseases, namely, Alzheimer's, Huntington's Disease, cerebral palsy; pharmaceutical preparations for the treatment of neurological disorders, namely, brain injury, spinal cord injury, seizure disorders; pharmaceutical preparations for the treatment of neuromuscular diseases and disorders, namely, cerebrovascular accident (stroke), Parkinson's disease, multiple sclerosis, myasthenia gravis, Huntington's disease; pharmaceutical preparations for the treatment of oncological diseases and disorders; pharmaceutical preparations for the treatment of ophthalmological diseases and disorders; pharmaceutical preparations for the treatment of renal diseases, cardiovascular diseases, liver diseases, pulmonary diseases, metabolic diseases, cancer, hematology, central nervous system diseases, diabetes, vascular diseases and fibrosis; pharmaceutical preparations for the treatment of the musculoskeletal system, namely, connective tissue diseases, bone diseases, spinal diseases, back pain, fractures, sprains, cartilage injuries; pharmaceutical preparations for the treatment of viral diseases, namely, herpes, hepatitis, Acquired Immune Deficiency Syndrome (AIDS); pharmaceutical preparations for treating gastrointestinal disorders; pharmaceutical preparations for treating respiratory diseases; pharmaceutical preparations for use in dermatology, namely dermatitis, skin pigmentation diseases and treatment of acne; pharmaceutical preparations for use in dermatology, namely, dermatitis, skin pigmentation diseases, sexually transmitted diseases; pharmaceutical preparations for use in the treatment of immunological disorders; pharmaceutical preparations for use in urology; pharmaceutical preparations namely, anti-inflammatories;


Classification kind code

11

Mark Details


Serial Number

1978407

Mark Type

Trademark

Legal History


Show more

Action TakenStatus
Submitted for opposition 190
on 16th Aug 2024
Registration Pending
Submitted for opposition 42
on 29th May 2024
Advertised
Submitted for opposition 26
on 2th May 2024
Approved
Submitted for opposition 27
on 2th May 2024
Approval Notice Sent
Submitted for opposition 22
on 28th Mar 2024
Search Recorded
Submitted for opposition 20
on 28th Mar 2024
Examiner's First Report
Submitted for opposition 287
on 29th Mar 2022
Pre-Assessment Letter Sent
Submitted for opposition 31
on 2th Aug 2019
Formalized
Submitted for opposition 1
on 1st Aug 2019
Created
Submitted for opposition 30
on 31st Jul 2019
Filed